Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -59.02 is 13893% below its 5-year average of 0.43, near the low end of its 5-year range (-59.02–3.65).
As of the fiscal period ended Tuesday, June 30, 2026. 509.15% below its 12-month average of -9.69.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -59.02.
DEBT TO EQUITY RATIO
-59.02
DEBT TO EQUITY RATIO AVG TTM
-9.69
DEBT TO EQUITY RATIO AVG 3Y
1.25
DEBT TO EQUITY RATIO AVG 5Y
0.43
DEBT TO EQUITY RATIO AVG 10Y
0.17
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-509.15%
CURRENT VS 3Y AVG
-4809.80%
CURRENT VS 5Y AVG
-13892.75%
CURRENT VS 10Y AVG
-34453.85%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.12
median of 649 covered companies
CURRENT VS SECTOR MEDIAN
-49286.62%
vs the sector median at left
Market Cap
$3.53B
Debt to Equity Ratio
3.91
TTM Avg
6.45
3Y Avg
3.52
5Y Avg
2.47
Market Cap
$3.53B
Debt to Equity Ratio
0.02
TTM Avg
0.03
3Y Avg
0.01
5Y Avg
0.02
Market Cap
$3.44B
Debt to Equity Ratio
0.07
TTM Avg
0.08
3Y Avg
0.13
5Y Avg
0.24
Market Cap
$3.60B
Debt to Equity Ratio
0.32
TTM Avg
0.06
3Y Avg
0.05
5Y Avg
0.05
Market Cap
$3.42B
Debt to Equity Ratio
0.06
TTM Avg
0.06
3Y Avg
0.10
5Y Avg
0.10
Market Cap
$3.35B
Debt to Equity Ratio
0.05
TTM Avg
1.17
3Y Avg
1.17
5Y Avg
1.17
Market Cap
$3.14B
Debt to Equity Ratio
0.03
TTM Avg
0.04
3Y Avg
0.05
5Y Avg
0.05
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Celcuity Inc. (CELC) | $3.52B | -59.02 | -9.69 | 1.25 | 0.43 |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.53B | 3.91 | 6.45 | 3.52 | 2.47 |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.53B | 0.02 | 0.03 | 0.01 | 0.02 |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | 0.07 | 0.08 | 0.13 | 0.24 |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.60B | 0.32 | 0.06 | 0.05 | 0.05 |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.42B | 0.06 | 0.06 | 0.10 | 0.10 |
| CareDx, Inc (CDNA)vs › | $3.40B | 0.05 | 0.08 | 0.10 | 0.08 |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.35B | 0.05 | 1.17 | 1.17 | 1.17 |
| Denali Therapeutics Inc. (DNLI)vs › | $3.14B | 0.03 | 0.04 | 0.05 | 0.05 |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.07B | 0.00 | 0.00 | 0.00 | 0.00 |
Debt/Equity
-59.02
Current Ratio
8.93
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -59.02 |
| 2026-03-31 | 3.65 |
| 2025-12-31 | 1.94 |
| 2025-09-30 | 2.74 |
| 2025-06-30 | 2.24 |
| 2025-03-31 | 1.14 |
| 2024-12-31 | 0.85 |
| 2024-09-30 | 0.65 |
| 2024-06-30 | 0.55 |
| 2024-03-31 | 0.28 |
| 2023-12-31 | 0.27 |
| 2023-09-30 | 0.40 |
| 2023-06-30 | 0.33 |
| 2023-03-31 | 0.29 |
| 2022-12-31 | 0.26 |
| 2022-09-30 | 0.35 |
| 2022-06-30 | 0.29 |
| 2022-03-31 | 0.24 |
| 2021-12-31 | 0.22 |
| 2021-09-30 | 0.20 |
| 2021-06-30 | 0.53 |
| 2021-03-31 | 0.01 |
| 2020-12-31 | 0.02 |
| 2020-09-30 | 0.02 |
| 2020-06-30 | 0.01 |
| 2020-03-31 | 0.01 |
| 2019-12-31 | 0.01 |
| 2019-09-30 | 0.01 |
| 2019-06-30 | 0.02 |
| 2019-03-31 | 0.02 |
| 2018-12-31 | 0.00 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
| 2017-12-31 | 0.00 |
| 2017-09-30 | 0.00 |
| 2017-06-30 | 1.52 |
| 2017-03-31 | 0.00 |
| 2016-12-31 | 0.00 |
| 2016-09-30 | 0.00 |
| 2016-06-30 | 0.00 |
| 2016-03-31 | 0.00 |
